US 12,011,390 B2
Lacrimal drug delivery device
Andrew Schieber, Laguna Niguel, CA (US); Linda Thai, Mission Viejo, CA (US); and Malik Kahook, Denver, CO (US)
Assigned to The Regents of the University of Colorado, a body corporate, Denver, CO (US)
Filed by THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, Denver, CO (US)
Filed on Nov. 11, 2021, as Appl. No. 17/524,610.
Application 17/524,610 is a continuation of application No. 16/302,514, granted, now 11,207,211, previously published as PCT/US2017/033277, filed on May 18, 2017.
Claims priority of provisional application 62/339,258, filed on May 20, 2016.
Prior Publication US 2022/0062037 A1, Mar. 3, 2022
Int. Cl. A61F 9/00 (2006.01); A61K 9/00 (2006.01); A61K 45/00 (2006.01)
CPC A61F 9/0008 (2013.01) [A61K 9/0051 (2013.01); A61K 45/00 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A lacrimal drug delivery device comprising:
a reservoir configured to hold a therapeutic agent, the reservoir configured to transition between a relaxed state and an expanded state;
a delivery guide;
a connector comprising:
a first lumen in fluid communication with the reservoir and configured to deliver the therapeutic agent from the reservoir to an eye of a subject;
a second lumen in fluid communication with the reservoir and configured to receive the delivery guide therein to deliver the therapeutic agent into the reservoir;
a hydrogel disposed within the first lumen and configured to control a flow rate of the therapeutic agent from the reservoir to the eye; and
a plug releasably couplable to the delivery guide, the plug configured to release from the delivery guide and seal the second lumen to prevent the therapeutic agent from flowing through the second lumen after the delivery guide delivers the therapeutic agent into the reservoir.